300725 Stock Overview Provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
PharmaBlock Sciences (Nanjing), Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for PharmaBlock Sciences (Nanjing) Historical stock prices Current Share Price CN¥35.40 52 Week High CN¥45.36 52 Week Low CN¥23.25 Beta 0.72 1 Month Change 2.94% 3 Month Change 29.96% 1 Year Change -5.37% 3 Year Change -74.78% 5 Year Change -32.65% Change since IPO -6.18%
Recent News & Updates
Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.20 in 3Q 2023) Oct 30
Investor sentiment deteriorates as stock falls 22% Oct 15
New minor risk - Share price stability Sep 30
PharmaBlock Sciences (Nanjing), Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 30
Investor sentiment improves as stock rises 26% Sep 27
Second quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.28 in 2Q 2023) Aug 17 See more updates
Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.20 in 3Q 2023) Oct 30
Investor sentiment deteriorates as stock falls 22% Oct 15
New minor risk - Share price stability Sep 30
PharmaBlock Sciences (Nanjing), Inc. to Report Q3, 2024 Results on Oct 24, 2024 Sep 30
Investor sentiment improves as stock rises 26% Sep 27
Second quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.28 in 2Q 2023) Aug 17
PharmaBlock Sciences (Nanjing), Inc. to Report First Half, 2024 Results on Aug 17, 2024 Jun 29
Dividend increased to CN¥0.31 Jun 10
PharmaBlock Sciences (Nanjing), Inc. Announces Dividend on Share A for the Year 2023, Payable on June 14, 2024 Jun 08
New minor risk - Share price stability May 29
New minor risk - Dividend sustainability Apr 29
PharmaBlock Sciences (Nanjing), Inc., Annual General Meeting, May 17, 2024 Apr 24
First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 1Q 2023) Apr 24
Investor sentiment deteriorates as stock falls 16% Apr 17
PharmaBlock Sciences (Nanjing), Inc. to Report Q1, 2024 Results on Apr 24, 2024 Mar 30
Investor sentiment improves as stock rises 18% Mar 15
Investor sentiment deteriorates as stock falls 16% Feb 01
PharmaBlock Sciences (Nanjing), Inc. to Report Fiscal Year 2023 Results on Apr 24, 2024 Dec 30 PharmaBlock Sciences (Nanjing), Inc.(SZSE:300725) dropped from Shenzhen Stock Exchange Component Index
New minor risk - Share price stability Nov 06
Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.49 in 3Q 2022) Nov 01
Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.41 in 2Q 2022) Aug 15
PharmaBlock Sciences (Nanjing), Inc. to Report First Half, 2023 Results on Aug 15, 2023 Jul 01
Pharmablock Sciences (Nanjing), Inc. Announces Final Dividend on Share A for 2022, Payable in June 13, 2023 Jun 07
Investor sentiment deteriorates as stock falls 21% Apr 28
First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.36 in 1Q 2022) Apr 23
Investor sentiment improves as stock rises 19% Mar 27
High number of new and inexperienced directors Nov 16
Investor sentiment improved over the past week Nov 01
Third quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.31 in 3Q 2021) Oct 27
Investor sentiment improved over the past week Oct 15
Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥1.61 in 2Q 2021) Aug 14
Now 23% undervalued Jul 13
Pharmablock Sciences (Nanjing), Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 13, 2022 Jun 08
Now 20% undervalued after recent price drop May 24
PharmaBlock Approves cash dividend for the year of 2021 May 21
Pharmablock Sciences (Nanjing), Inc. Proposes Final Cash Dividend for the Year 2021 May 02
First quarter 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.35 in 1Q 2021) Apr 30
High number of new and inexperienced directors Apr 27
Now 22% undervalued after recent price drop Apr 09
Investor sentiment improved over the past week Mar 22
Now 21% undervalued after recent price drop Feb 23
PharmaBlock Appoints Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs Feb 17
Now 21% undervalued after recent price drop Jan 29
Investor sentiment deteriorated over the past week Jan 06
Investor sentiment deteriorated over the past week Nov 03
Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.29 in 3Q 2020) Oct 28
Investor sentiment improved over the past week Aug 06
Second quarter 2021 earnings released: EPS CN¥1.61 (vs CN¥0.32 in 2Q 2020) Jul 31
First quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.19 in 1Q 2020) Apr 25
Full year 2020 earnings released: EPS CN¥1.29 (vs CN¥1.06 in FY 2019) Mar 26
PharmaBlock Sciences (Nanjing), Inc. Appoints Yu Shanbao as A Director Feb 26
PharmaBlock Sciences (Nanjing), Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021 Feb 24
New 90-day high: CN¥188 Feb 06
New 90-day high: CN¥173 Jan 22
New 90-day high: CN¥156 Jan 07
PharmaBlock Enters Strategic Partnership with Ascentage Pharma Dec 13
New 90-day low: CN¥113 Nov 25
Third quarter earnings released Oct 29
New 90-day high: CN¥142 Oct 13
New 90-day high - CN¥135 Aug 27
First half earnings released Aug 27
PharmaBlock Sciences (Nanjing), Inc. to Report First Half, 2020 Results on Aug 27, 2020 Aug 11
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) cancelled the acquisition of the remaining 68.85% stake in Nanjing Yaojian Kangke Pharmaceutical Technology Co., Ltd. from Zhao Ke Jul 30
PharmaBlock Sciences (Nanjing), Inc. announced that it expects to receive CNY 930 million in funding Jul 18 Shareholder Returns 300725 CN Pharmaceuticals CN Market 7D -0.4% -1.0% 0.4% 1Y -5.4% -3.0% 12.3%
See full shareholder returns
Return vs Market: 300725 underperformed the CN Market which returned 9.8% over the past year.
Price Volatility Is 300725's price volatile compared to industry and market? 300725 volatility 300725 Average Weekly Movement 11.6% Pharmaceuticals Industry Average Movement 7.4% Market Average Movement 8.8% 10% most volatile stocks in CN Market 13.0% 10% least volatile stocks in CN Market 5.8%
Stable Share Price: 300725's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300725's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.
Show more PharmaBlock Sciences (Nanjing), Inc. Fundamentals Summary How do PharmaBlock Sciences (Nanjing)'s earnings and revenue compare to its market cap? 300725 fundamental statistics Market cap CN¥7.04b Earnings (TTM ) CN¥175.11m Revenue (TTM ) CN¥1.56b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 300725 income statement (TTM ) Revenue CN¥1.56b Cost of Revenue CN¥960.16m Gross Profit CN¥601.47m Other Expenses CN¥426.37m Earnings CN¥175.11m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.88 Gross Margin 38.52% Net Profit Margin 11.21% Debt/Equity Ratio 51.5%
How did 300725 perform over the long term?
See historical performance and comparison Dividends
0.9% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 13:05 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources PharmaBlock Sciences (Nanjing), Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kai Wang Citic Securities Co., Ltd. Xiao Wei Lin Everbright Securities Co. Ltd. Yuan Yuan Sun Industrial Securities Co. Ltd.
Show 3 more analysts 
